Safety and Tolerability of MEDI0562, an OX40 Agonist mAb, in Combination with Durvalumab or Tremelimumab in Adult Patients with Advanced Solid Tumors

By sjmartinez • September 1, 2022

Goldman JW, Piha-Paul SA, Curti B, Pedersen KS, Bauer TM, Groenland SL, Carvajal RD, Chhaya V, Kirby G, McGlinchey K, Hammond SA, Streicher K, Townsley DM, Chae YK, Voortman J, Marabelle A, Powderly J. Safety and Tolerability of MEDI0562, an OX40 Agonist mAb, in Combination with Durvalumab or Tremelimumab in Adult Patients with Advanced Solid Tumors. Clin Cancer Res. 2022 Sep 1;28(17):3709-3719. doi: 10.1158/1078-0432.CCR-21-3016. PMID: 35699623.

Tags: Hematology/Oncology, Publications

The Next Chapter of Cancer Immunology Research

Jaffee EM, Ribas A. The Next Chapter of Cancer Immunology Research. Cancer Immunol Res. 2026 Jan 8;14(1):8-9. doi: 10.1158/2326-6066.CIR-25-1391. PMID: 41502310.

Transarterial Radioembolization (TARE) Complicated by a Mycotic Aneurysm and Bleeding: A Case Presentation and Literature Review

Hu EH. Transarterial Radioembolization (TARE) Complicated by a Mycotic Aneurysm and Bleeding: A Case Presentation and Literature Review. Cureus. 2025 Dec 4;17(12):e98484. doi: 10.7759/cureus.98484. PMID:[...]

CRISPR/Cas strategies to enhance CAR T-cell function and persistence via metabolic reprogramming

Wang MR, Mu W, Zhen A, Kitchen SG. CRISPR/Cas strategies to enhance CAR T-cell function and persistence via metabolic reprogramming. Trends Biotechnol. 2026 Jan 5:S0167-7799(25)00499-8.[...]